Trials / Completed
CompletedNCT01922661
Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to assess the safety and tolerability of single ascending doses of subcutaneously (SC) administered REGN1908-1909 in allergic, adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN1908-1909 | |
| OTHER | placebo |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2013-08-14
- Last updated
- 2014-06-10
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01922661. Inclusion in this directory is not an endorsement.